Abstract
Standardized reporting is more and more routinely implemented in clinical practice, and such structured reports have a major impact on a large variety of medical fields, such as laboratory medicine, pathology, and, recently, radiology. Notably, the field of nuclear medicine is constantly evolving as novel radiotracers for numerous clinical applications are developed. Thus, framework systems for standardized reporting in this field may increase clinical acceptance of new radiotracers, allow for inter- and intracenter comparisons for quality assurance, and be used in global multicenter studies to ensure comparable results and enable efficient data abstraction. In the last couple of years, several standardized framework systems for PET radiotracers with potential theranostic applications have been proposed. These include systems for prostate-specific membrane antigen–targeted PET agents to diagnose and treat prostate cancer, and systems for somatostatin receptor–targeted PET agents to diagnose and treat neuroendocrine neoplasia. In the present review, the framework systems for these 2 types of cancer will be briefly introduced, followed by an overview of their advantages and limitations. In addition, potential applications will be defined, approaches to validate such concepts will be proposed, and future perspectives will be discussed.
In general, standardized reporting has recently become implemented more routinely in clinical practice. Such structured reports, which, in some contexts, were introduced as early as the 1970s, have had a major impact on a large variety of medical fields, such as laboratory medicine (1), pathology (2), and, recently, radiology (3,4). Notably, the field of nuclear medicine is constantly evolving as novel radiotracers for numerous clinical applications are developed and administered in the clinical setting (5–8). Thus, framework systems for standardization of reporting in this field would be particularly necessary. Nuclear medicine reporting frameworks may increase clinical acceptance of novel radiotracers that are being transitioned into routine clinical practice, open avenues for inter- and intrareader and inter- and intracenter comparisons for quality assurance purposes, and be used in national or global multicentric studies to more efficiently enable comparison of datasets from different centers.
NOTEWORTHY
Several framework systems for both PSMA-targeted PET for PCa and SSTR-targeted PET for NEN have been introduced.
For PSMA-targeted PET, these systems consist of a consensus paper written on behalf of the EANM, PSMA-RADS, and PROMISE.
For SSTR-targeted PET, these systems consist of the NETPET grade and SSTR-RADS.
Future directions should focus on validating such systems or defining a single universal framework system per radiotracer.
In the last 2 decades, somatostatin receptor (SSTR) agonists such as 68Ga-DOTATOC, 68Ga-DOTATATE, and 68Ga-DOTANOC and subsequent therapies with either 177Lu- or 90Y-labeled analogs have become a standard of care for patients with SSTR-expressing tumors throughout the world (9–12). In a similar vein to SSTR-targeted PET for neuroendocrine neoplasia (NEN), the use of radiotracers for prostate-specific membrane antigen (PSMA), labeled with either 68Ga or 18F, is rapidly becoming a new standard of care for prostate cancer (PCa) imaging throughout much of the world, in particular because the theranostic concept can potentially be applied in PCa as well (13–16).
To aid interpretation of 18F-FDG PET findings in determining oncologic response to therapy, there have been several proposed systems, such as the Deauville/Lugano criteria and PERCIST 1.0. These systems are specifically less focused on providing diagnostic information on baseline imaging studies (17,18). However, in light of the evolving field of theranostics for NEN and PCa, in which findings on baseline diagnostic imaging portend treatment success with radioligand therapies, the field is in need of baseline criteria for evaluating either PSMA- or SSTR-targeted PET scans.
This clinical need has not gone unnoticed, and a great deal of recent progress has been made by the introduction of novel standardized framework systems for the evaluation of various receptor-based radiotracers. For PCa, these systems include the PSMA Reporting and Data System (RADS), version 1.0; the Prostate Cancer Molecular Imaging Standardization Evaluation (PROMISE); and a proposed standardized framework system for 68Ga-PMSA PET/CT for the detection of recurrent lesions, which was written on behalf of the European Association of Nuclear Medicine (EANM) (19–21) and is referred to here as the EANM Consensus Paper (21). For NEN, the framework systems include SSTR-RADS, version 1.0, which applies the concept of PSMA-RADS to NEN and considers SSTR-specific details (22). Notably, both RADS framework systems (PSMA- and SSTR-RADS) have been recently summarized under the umbrella term molecular imaging (MI) RADS, as these systems can be applied reciprocally (i.e., imaging interpreters who are familiar with one RADS system should be able to learn the other) (23). Another NEN-specific system is the NETPET grade, which uses a dual-radiotracer approach (SSTR-targeted and 18F-FDG PET). The NETPET scoring system will also be reviewed here; however, this system has been developed as a prognostic biomarker to capture the findings of a dual-radiotracer assessment in a single parameter rather than as a method for evaluating a baseline SSTR-PET scan (24).
In the present review, these concepts will be briefly introduced, followed by an overview of their advantages and limitations. In addition, potential applications will be defined, approaches to validate such concepts will be proposed, and future perspectives will be discussed.
PATIENT POPULATION
Because the data presented here comprise a retrospective analysis of routinely acquired data, the local ethic committee waived the need for further approval. All patients gave written informed consent to the procedures and to scientific analysis of the obtained data.
STANDARDIZED REPORTING SYSTEMS FOR PCA
EANM Consensus Paper
On behalf of the EANM, Fanti et al. (21) proposed a standardized imaging interpretation system for 68Ga-PSMA that uses the following criteria: first, anomalous findings, defined as suggestive radiotracer uptake above physiologic background, are recorded. Second, all these sites are classified as “pathologic” for PCa, unless another explanation is apparent, that is, false-positive findings, such as PSMA-avid Paget disease (25). Third, the anatomic localization is considered (up to 5 lesions). Of note, Fanti et al. not only proposed the system but also performed a concordance assessment among multiple readers. Notably, an interobserver agreement (Krippendorf α) of 0.64 (i.e., moderate agreement) was achieved when readers had to evaluate whether the investigated target lesions were suggestive of a pathologic, uncertain, or nonpathologic entity. After conducting several Delphi rounds to reach consensus between the different study sites, the following amendments were introduced: first, a finding observed only on CT will be classified as “abnormal” but “uncertain”; second, in patients with residual prostatic tissue (no radical prostatectomy) and sources of artifact (e.g., brachytherapy seeds), the intensity of focal uptake is important in deciding whether the lesion should be classified as “pathologic”; and third, recurrence sites (other than the site of primary treatment) need increased attention and, again, in cases of intense focal uptake, can be considered “pathologic.”
This framework system has also been further validated: in 49 subjects from 7 study sites, a moderate agreement among readers was achieved. Notably, several Delphi rounds were conducted and led to further improvement of the system, reduced the number of discordant cases, and achieved consensus among the readers. Thus, the EANM consensus paper aimed to identify possible disagreements among multiple experts and provide suggestions for appropriate reporting (21). However, a definition for the level of uptake, as defined in PROMISE, is not given. Further, a translation of the derived findings into an alphanumeric code, as suggested in PSMA-RADS, may facilitate memorizing this system (19–21). Nonetheless, as a major achievement of the EANM consensus paper, the authors provide a definition of the findings that can be seen as uncertain, which, in turn, may lay the groundwork for fusing this system with the 5-point scale provided in PSMA-RADS and the level of uptake as defined in PROMISE (20,21).
MI-RADS
A recent effort has summarized 2 RADS framework systems proposed to date for MI (i.e., PSMA- and SSTR-targeted PET/CT interpretation, namely PSMA- and SSTR-RADS) under a single umbrella term: MI-RADS (23). MI-RADS systems are exclusively based on imaging findings (site of disease and intensity of radiotracer uptake), and both refer to a 5-point Likert scale (from 1, no evidence of disease/definitively benign, to 5, high certainty that PCa or NEN is present). This underlying identical structure allows both MI-RADS systems to be used reciprocally (23). Supplemental Table 1 provides a precise overview of MI-RADS (supplemental materials are available at http://jnm.snmjournals.org). In the following, we will first introduce PSMA-RADS for PCa.
PSMA-RADS, Version 1.0
Rowe et al. suggested a 5-point scale for the interpretation of PSMA-targeted PET/CT for PCa and also provided recommendations for appropriate next steps in the work-up of indeterminate findings (19). In brief, PSMA-RADS-1A describes a scan without abnormal radiotracer uptake (i.e., normal biodistribution of a PSMA imaging agent), whereas PSMA-RADS-1B findings are benign lesions that demonstrate radiotracer uptake and have been confirmed by histologic diagnosis or definitively characterized as benign on imaging (e.g., a PSMA-avid thyroid nodule that has been previously biopsied and found to be an adenoma). PSMA-RADS-2 describes sites with low-level uptake (no more than the blood pool level), which are almost certainly benign and would be atypical for PCa. PSMA-RADS-3 includes indeterminate lesions, and thus, these lesions may trigger further work-up. In PSMA-RADS-4 lesions, PCa is highly likely because of intense uptake in a site typical for PCa but without an abnormality on anatomic imaging. PSMA-RADS-5 lesions demonstrate intense PSMA uptake in a site typical for PCa, with corresponding evidence on conventional imaging, and PCa is almost certainly present (Supplemental Table 1) (19). As proposed in its successor, SSTR-RADS (22), an overall PSMA-RADS score assessment may be useful to provide the referring clinician with an overall scan impression in the summary statement or impression of the report. Further, up to 5 target lesions are selected and given individual PSMA-RADS scores. On the basis of this target lesion assessment, the overall PSMA-RADS score can be defined as the highest score of any of the individual target lesions. Figure 1 shows an overall PSMA-RADS score assessment.
Example of overall assessment using PSMA-RADS, version 1.0 (19) in 76-y-old man with history of proven PCa who underwent 18F-DCFPyL PET/CT for staging. (A) Whole-body maximum-intensity projection demonstrates suggestive radiotracer uptake (arrowhead). (B–D) Visualization of uptake in left external iliac lymph node (arrows) on axial CT (B), PET (C), and PET/CT (D). Experienced reader classified this uptake as PSMA-RADS-4 because on CT there is no corresponding pathologic finding. (E–G) Because equivocal uptake in bone lesion would not be atypical on anatomic imaging for PCa, finding in ala of left sacrum (arrows) on axial CT (E), PET (F), and PET/CT (G) was classified as PSMA-RADS-3B. Overall RADS score was 4 (Supplemental Table 1).
Notably, the PSMA-RADS scoring system has recently been further validated. PSMA-RADS-3A (soft-tissue sites) and -3B (bone lesions) can refer to findings that have low levels of uptake and lack a correlative anatomic finding (19). In patients with indeterminate findings and available follow-up imaging, the majority (75.0%) of PSMA-RADS-3A lesions demonstrated changes on subsequent imaging compatible with the presence of PCa, whereas only a minority (21.4%) of PSMA-RADS-3B indeterminate bone lesions showed changes on follow-up imaging suggestive of underlying PCa. These findings confirm the necessity for a category in the PSMA-RADS grading system for indeterminate lesions (26). In addition, the PSMA-RADS system has also been evaluated in a prospective interobserver agreement setting using 50 18F-DCFPyL PET/CT scans. Four readers (2 experienced and 2 inexperienced), masked to the clinical status of the patients, performed an evaluation of all scans independently and evaluated PSMA-RADS on a target lesion–based, an organ-based, and an overall PSMA-RADS score–based level. The interobserver agreement for PSMA-RADS scoring among identical target lesions was good (intraclass correlation coefficient, ≥0.60). For lymph nodes and the overall scan impression (Fig. 2), an excellent interobserver agreement was derived (intraclass correlation coefficient, 0.79 and 0.84, respectively). Given the high concordance rate in this study, even among readers with different levels of experience, PSMA-RADS may be able to be implemented in the collection of data for large prospective trials (27).
Overall PSMA RADS scoring for 4 masked readers (ER = experienced reader; IR = inexperienced reader), all of whom evaluated 50 18F-DCFPyL PET/CT scans. Often, characterizing lesion as PSMA-RADS-1B involves previous conventional imaging or histologic diagnosis; as such, PSMA-RADS-1A and -1B were subsumed under PSMA-RADS-1 in this masked interobserver agreement study. For overall scan impression, high interreader agreement rate, even among IRs, was noted. (Reprinted from (27).)
PROMISE
Eiber et al. proposed an MI-TNM classification (“miTNM,” version 1.0) as a standardized framework system for PSMA-ligand PET/CT and PET/MRI (20). This scoring system determines the uptake on a 4-point scale in visual assessment (“miPSMA expression score,” with different levels of uptake noted relative to the normal uptake in the blood pool, liver, and parotid glands). Of note, in PSMA-targeted PET scans with liver-dominant excretion PET agents, such as 18F-PSMA 1007, the liver is replaced by the spleen (20,28). Moreover, categorization of local tumor takes the extent and organ confinement into account (miT0, no local tumor; miT2, organ-confined tumor with “u” [unifocality] or “m” [multifocality]; miT3, non–organ-confined tumor with “a” [extracapsular extension] or “b” [tumor invading seminal vesicles]; miT4, tumor invading adjacent structures other than seminal vesicles). A strength of PROMISE is that it directly addresses local tumor staging. To evaluate the intraprostatic tumor extension, a sextant segmentation of the prostate gland was proposed, which in turn may provide detailed information for biopsies.
Moreover, in PROMISE, the pelvic node metastases are assessed and categorized as no positive lymph node (miN0), single involved nodal regions (miN1a), or multiple involved nodal regions (miN1b), with further demarcation as to the exact nodal groups involved: miN1a/b: II (internal iliac), EI (external iliac), CI (common iliac), OB (obturator), PS (presacral), or OP (other pelvic [should be specified]). Finally, the extrapelvic nodes are included (miM1a: RP [retroperitoneal], SD [supradiaphragmatic], or OE [other extrapelvic]), as well as distant metastases (miM1b [referring to bone] or miM1c [referring to other sites of organ involvement]). Skeletal involvement is classified as being unifocal (Uni), oligometastatic (Oligo, ≤3 sites), disseminated (Diss), or diffuse bone marrow (Dmi). The authors recommend documenting diagnostic certainty on a 5-point scale (“consistent with PCa” to “no evidence of disease”). In addition, the final diagnosis should be reported as positive for PCa, negative for PCa, or, if further work-up using other techniques is available, equivocal for PCa. Taken together, PROMISE includes information on location, disease distribution pattern, level of PSMA expression, and level of certainty that PCa is present. Figure 3 gives an example of primary staging using 68Ga-PSMA-11 PET/high-resolution T2-weighted MRI in a 65-y-old man with histopathologically proven PCa. PROMISE has been applied to this patient with a result of miT3aN1(OBL)M0 (with L referring to the left side of obturator lymph node involvement) (20).
Example of PROMISE (20) for primary staging using 68Ga-PSMA-11 PET/high-resolution T2-weighted MRI in 65-y-old man with histopathologically proven PCa. (A) Maximum-intensity projection shows intermediate PSMA expression (equivalent to score 2) in prostate gland (solid arrow) and high PSMA expression (score 3) in regional pelvic lymph node (dotted arrow). (B and C) Axial (B) and coronal (C) PET/MRI, with PET at top, hybrid imaging in middle, and MRI at bottom, demonstrate bilateral T2-hypointense lesions that correspond to uptake on PSMA-ligand PET and exceed prostate margin, indicating extracapsular extension (T3a, arrows). (D) Axial imaging shows single lymph node metastasis in left obturator region (arrows). Final diagnosis according to PROMISE was miT3aN1(OBL)M0. Sextant segment boundaries are shown on coronal images in white. (Reprinted from (20).)
Potential Applications
Similar to 18F-FDG, a considerable number of studies have reported pitfalls in reading PSMA-targeted PET scans. As a physiologic radiotracer uptake site, ganglia can be misinterpreted, in particular in terms of mistaking such structures for abdominal lymph nodes (e.g., celiac ganglia) (29–31). Benign pathologic states may also mimic PCa, such as fibrous dysplasia, healing bone fractures, or granulomatous diseases (e.g., sarcoidosis) (25,32–34). Nonprostatic malignancies that may demonstrate uptake of PSMA-targeted radiotracers include, but are not limited to, pancreatic NEN, squamous cell carcinoma of the oropharynx, hepatocellular carcinoma, and renal cell carcinoma (25,35–38). Although the detection rate and recognition of potentially confusing false-positive or false-negative findings on PSMA-targeted PET scans can almost certainly be increased by appropriate training, the way in which PSMA-RADS may live up to its full potential is in providing readers with a mechanism to formalize uncertainty about such findings and to recommend any further workup to clinicians. Intended to serve as a readily applicable system for any imaging expert, PSMA-RADS is simple and easy to memorize and use and, thus, may serve as a powerful tool to assist in diagnosis in a busy clinical PCa practice. However, as a drawback, PSMA-RADS uses terms such as typical or atypical for sites of disease, and follow-up versions of this system should clarify such phrases to increase the reader’s confidence (19,39). PSMA-RADS does not stipulate the inclusion of in-depth anatomic details, unlike the EANM consensus paper and PROMISE, which thoroughly evaluate PSMA-targeted PET/CT or PET/MRI findings and include many details on imaging interpretation (20,21). This characteristic may pave the way for incorporating the latter systems into large clinical trials, in which distinct, numerous parameters should be obtained to enrich the dataset and allow for fine parsing of patient subsets for outcomes research. PROMISE also includes visual criteria using an internal organ reference of PSMA uptake—a consideration that, although requiring further confirmation, may persuade principal investigators to apply PROMISE in a research setting (20,39). In addition, threshold sensitivity may also have an impact on the miPSMA expression score (39). PROMISE is the only system reviewed here that has been used in a preclinical setting to investigate the in vivo relationship between 68Ga-PSMA-11 PET/CT and PSMA expression in a murine model of PCa (40). A major advantage of the system proposed by the EANM is that it has been assessed in a Delphi approach of consensus, which serves as a reliable means for categorizing tumor entities (21,41) and may be a significant advantage for training less experienced readers. Currently, all PCa framework systems lack treatment recommendations for endoradiotherapies. However, given the evolving field of 68Ga/18F/177Lu-PSMA theranostics, future versions should consider providing instructions on when to initiate such treatments.
Table 1 summarizes limitations and advantages of framework systems for evaluating PSMA-targeted PET/CT scans for PCa patients.
Head-to-Head Comparison of Standardized Framework Systems for PSMA PET/CT for Evaluating PCa
STANDARDIZED REPORTING SYSTEMS FOR NEN
The NETPET Grade
In contrast to the framework systems for PCa, the NETPET grade intends not to evaluate an isolated baseline examination but to provide a dual SSTR/18F-FDG grading scheme. This intention is mainly due to the assumption that the most 18F-FDG–avid lesion (relative to its uptake on SSTR-PET) may also reflect the most aggressive phenotype of the disease present. On a 5-point scale, the spectrum of results seen on both PET scans is as follows: P0 is negative on both PET studies; P1 is SSTR-positive but 18F-FDG–negative; P2 through P4 are positive on both PET studies, but their intensities relative to each other differ (i.e., these lesions represent an intermediate group on dual-radiotracer imaging); and P5 is SSTR-negative but 18F-FDG–positive (24,42). Notably, analogous to the EANM consensus paper on PSMA-targeted PET, the NETPET grade has been validated in the same paper (21,24). Kaplan–Meier curves presented for subjects grouped to P1, P2–P4, and P5 revealed a significant separation of overall survival for those 3 groups, indicating that the NETPET grade may serve as a predictor for outcome. However, the study cohort included different sites of primary tumor and different treatments (only parts of the cohort were treated with peptide receptor radionuclide therapy [PRRT]) (24).
SSTR-RADS, Version 1.0
Analogous to PSMA-RADS, a standardized framework system for interpreting SSTR-targeted PET/CT scans has recently been introduced and has been given the moniker SSTR-RADS (22). As part of MI-RADS (23), SSTR-RADS also uses a 5-point scale (1, benign, to 5, NEN almost certainly present) and is based exclusively on imaging findings (site of disease and intensity of radiotracer uptake); however, it refers to SSTR-targeted PET and NEN-specific details. SSTR-RADS-1 indicates findings that are known to be benign (confirmed by previous biopsy or with a pathognomonic appearance on conventional anatomic imaging) and includes SSTR-RADS-1A (normal biodistribution) and SSTR-RADS-1B (increased focal uptake but definitively benign by histology or imaging). SSTR-RADS-2 lesions are likely benign and describe soft-tissue sites or bone lesions atypical for metastatic NEN (e.g., strongly suspected to be degenerative, such as a Schmorl node). SSTR-RADS-3 includes indeterminate lesions and will often require further work-up. SSTR-RADS-4 (NEN highly likely) includes intense uptake in a site typical for NEN but lacks definitive findings on CT. SSTR-RADS-5 indicates a lesion in which NEN is almost certainly present, and the site of intense radiotracer uptake on SSTR-PET corresponds to an anatomic abnormality (Supplemental Table 1). Those SSTR-RADS classifications not only have recommendations for further work-up (biopsy or imaging) but also propose at which time-point to initiate PRRT with either 177Lu- or 90Y-labeled agents. The most dominant lesion (largest and with the most intense uptake) will overrule the other target lesions, and this representative lesion defines the overall SSTR-RADS score. With an overall SSTR-RADS-1 to -3, PRRT with hot somatostatin analogs should not be considered, whereas for an overall SSTR-RADS-4 or -5, PRRT is recommended; however, common practical guidelines still apply (22,43). In Supplemental Figures 1 and 2, SSTR-RADS has been applied to SSTR-PET/CT (Supplemental Fig. 1, overall SSTR-RADS score of 5, and Supplemental Fig. 2, overall score of 3D).
Potential Applications
SSTR-RADS was formulated as a system to assess the baseline SSTR-targeted PET and gives recommendations for both further work-up and treatment. In this regard, it may guide the referring treating physician to consider PRRT with 177Lu- or 90Y-labeled compounds. Moreover, it takes the level of uptake into account while using an internal organ reference. As part of MI-RADS, SSTR-RADS is based on the initial proposed framework system PSMA-RADS (although SSTR-targeted PET and NEN-specific details have been implemented in SSTR-RADS), and thus, both systems can be used reciprocally (23).
No validation studies with SSTR-RADS have yet been performed, unlike the NETPET grade, which has already proven its prognostic potential in a retrospective setting. When a dual-radiotracer approach of SSTR/18F-FDG PET/CT was combined in a single parameter, this framework system showed its capability as an outcome predictor (24). However, a dual-radiotracer approach is not performed routinely during follow-up, and thus, SSTR-RADS may serve as a reliable tool to investigate both baseline and follow-up scans. Its relevance for clinical practice is also evidenced by the recognition of pitfalls on SSTR-targeted PET/CT and by the associated recommendations for both work-up and treatment (e.g., indication for PRRT) (44).
Table 2 summarizes limitations and advantages of both systems for evaluating SSTR-targeted PET/CT.
Head-to-Head Comparison of Standardized Framework Systems for SSTR-PET/CT for Evaluating NEN
RECOMMENDATIONS FOR FUTURE VALIDATION AND A GLIMPSE AT FUTURE DIRECTIONS
Recommendations for Future Validation
Before testing in real-world scenarios, the reproducibility and robustness of the standardized framework systems reviewed here should be proven (45). Thus, several steps for validation should be pursued. First, inter- and intraobserver agreement studies, ideally with multiple centers and multiple readers with different levels of experience, should be performed (27). Second, although it is not possible to biopsy every single investigated target lesion, indeterminate lesions should be identified and compared with follow-up imaging findings when pathologic results are not available (26). Third, validation with different radiotracers may be indispensable, because the biodistribution of PSMA radioligands, even with similar radioisotopes, may differ (e.g., the biodistribution among normal organs using either 18F-PSMA-1007 or 18F-DCFPyL) (28,46). Fourth, validation of the detection rate of primary and metastatic disease with correlations to biopsy-driven histopathologic assessments are of importance to receive ultimate evidence (39). Fifth, the motivation to learn such standardized reporting systems should be evaluated; the change in a reader’s confidence in interpreting PET/CT when such systems have been applied should be measured, with theranostic implications, and the implementation rate in clinical practice should be investigated. Finally, the frameworks reviewed here aim to provide structured reporting systems for both PCa and NEN; however, MI per se may still remain rather asemantic (i.e., the language used in a report needs to be conventionally associated to meanings) (47).
Future Directions
Much progress can be made toward more global standardization and rapid clinical implementation by creatively fusing the different existing systems—for example, by defining a single universal framework system per radiotracer under the umbrella of the different nuclear medicine societies. Such an approach may expedite transfer from leading institutions to smaller PET centers, open avenues for more tailored treatment decisions, allow for intra- and intercenter comparisons, and pave the way for adoption in multicenter studies.
Such framework systems should also be developed for other theranostic pairs, such as 68Ga-pentixafor/177Lu-pentixather, which target the C-X-C chemokine receptor CXCR4 (6). Other potential theranostic twins may include the fibroblast activation protein–targeting 68Ga-/90Y-FAPI04 or the 177Lu-labeled and bombesin peptides for the gastrin-releasing peptide receptor (5,7).
DISCUSSION AND CONCLUSION
Given the indispensable need for harmonization of the interpretation of PET radiotracers with potential theranostic applications, several framework systems for both PSMA-targeted PET for PCa and SSTR-targeted PET for NEN have been introduced in the last couple of years (19–24). Existing framework systems for interpretation of imaging findings with 18F-FDG (Lugano, PERCIST) mainly allow for an overall assessment of treatment response, but theranostic radiotracers need baseline criteria to identify potential candidates for subsequent endoradiotherapies (48,49). In addition, such criteria would be helpful to standardize collected data for large, multicenter trials (50). For PCa, 3 framework systems have been proposed: PROMISE provides an in-depth evaluation of imaging-based findings, in particular for anatomic details (e.g., primary tumor location on sextant basis) (20). In contrast, the 5-point scale of PSMA-RADS is easy to memorize and use and, thus, may serve as a powerful tool to assist in diagnosis in a busy clinical PCa practice (19). Moreover, PSMA-RADS has also been validated in a prospective interobserver agreement setting with overall high concordance rates, even among inexperienced readers (27). In a similar vein, the EANM consensus paper has also been further validated in a multicenter assessment, and consensus has been defined in a sophisticated approach conducting several Delphi rounds with expert readers (21).
For NEN, SSTR-RADS has recently been introduced, a system that is based on the PSMA-RADS system but takes SSTR-targeted PET- and NEN-specific details into account (22). Both PSMA- and SSTR-RADS have recently been summarized under a single umbrella term that describes the application of RADS for molecular oncology imaging (MI-RADS). MI-RADS systems can be applied reciprocally; that is, imaging interpreters who are familiar with PSMA-RADS should be able to learn SSTR-RADS as well (19,22,23). The NETPET system consolidates the findings of SSTR-targeted and 18F-FDG PET in a single parameter and provides treatment recommendations based on imaging findings (24).
Future studies are warranted to more completely validate such framework systems, such as interobserver agreement studies on a larger scale or correlations of imaging findings with histopathologic results (27,39). In addition, consensus conferences are needed to further standardize these framework systems, ideally in a single universal framework system per radiotracer.
DISCLOSURE
Funding was provided by Progenics Pharmaceuticals, the Prostate Cancer Foundation Young Investigator Award, and National Institutes of Health grants CA134675, CA183031, CA184228, and EB024495. This project has also received funding from the European Union’s Horizon 2020 Research and Innovation Program under Marie Sklodowska-Curie grant agreement 701983. Martin Pomper is a coinventor on a patent covering 18F-DCFPyL and is entitled to a portion of any licensing fees and royalties generated by this technology. This arrangement has been reviewed and approved by the Johns Hopkins University in accordance with its conflict-of-interest policies. He has also received research funding from Progenics Pharmaceuticals, the licensee of 18F-DCFPyL. Michael Gorin has served as a consultant to Progenics Pharmaceuticals, and he, Kenneth Pienta, and Steven Rowe have received research funding from Progenics Pharmaceuticals. No other potential conflict of interest relevant to this article was reported.
Footnotes
Published online Feb. 22, 2019.
- © 2019 by the Society of Nuclear Medicine and Molecular Imaging.
REFERENCES
- Received for publication November 14, 2018.
- Accepted for publication December 29, 2019.
Jump to section
Related Articles
Cited By...
- Somatostatin Receptor Imaging and Theranostics: Current Practice and Future Prospects
- High Interobserver Agreement for the Standardized Reporting System SSTR-RADS 1.0 on Somatostatin Receptor PET/CT
- The Changing Face of Nuclear Cardiology: Guiding Cardiovascular Care Toward Molecular Medicine
- Proposal for Systemic-Therapy Response-Assessment Criteria at the Time of PSMA PET/CT Imaging: The PSMA PET Progression Criteria